Background illustration for clinical trials search

Pancreatic Cancer Clinical Trials

Browse 1,722 pancreatic cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Modernizing Instructions to Improve Treatment Participation of Subjects During Their First Radiotherapy

for
Cancer
Location: Gainesville FL
Sponsor: University of Florida

Sex: All

Age: 18 - 70+

Code: NCT06246409

Recruiting

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

for
Gastric Cancer, Gastro-esophageal Junction Cancer,
Location: Jacksonville FL, Rochester MN
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06005493

Phase 1, Phase 2, Recruiting

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

for
Solid Tumors, Advanced Solid Tumor
Location: Fairfax VA, Houston TX, San Antonio TX
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT07181681

Phase 1, Recruiting

The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials

for
Cancer
Location: The Bronx NY, Scranton PA, Dickson City PA,
Sponsor: Eastern Cooperative Oncology Group

Sex: All

Age: 18+

Code: NCT06756607

Recruiting

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

for
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary,
Location: Providence RI, New Haven CT, New York NY, Baltimore MD,
Sponsor: Volastra Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05902988

Phase 1, Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Comprehensive Health Assessment for My Plan: Initial Implementation Study (CHAMP Implementation Study)

for
Cancer, Older Adults
Location: Toronto
Sponsor: University of Toronto

Sex: All

Age: 70+

Code: NCT06464471

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

for
Solid Tumor
Location: New York NY, Tampa FL, Augusta GA, Chicago IL,
Sponsor: Eisai Inc.

Sex: All

Age: 18+

Code: NCT04300556

Phase 1, Phase 2, Recruiting

Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Boston MA, Providence RI, New Haven CT,
Sponsor: Debiopharm International SA

Sex: All

Age: 12+

Code: NCT04855656

Phase 1, Recruiting

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

for
Select Advanced Solid Tumors
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06598371

Phase 1, Phase 2, Recruiting

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

for
Nausea, Vomiting,
Location: New York NY, Tamarac FL, Savannah GA, Charlotte NC,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07169851

Phase 2, Recruiting

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

for
Advanced Malignant Solid Neoplasm,
Location: Columbus OH
Sponsor: Yuanquan Yang

Sex: All

Age: 18+

Code: NCT06470971

Phase 2, Recruiting

Evaluation of Outcomes From Treatment of Benign or Malignant Pancreatic Diseases

for
Benign or Malignant Pancreatic Diseases
Location: Richardson TX
Sponsor: Methodist Health System

Sex: All

Age: 18+

Code: NCT04055571

Recruiting

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

for
Advanced Solid Tumors With KRAS G12C Mutations,
Location: Boston MA, Philadelphia PA, Fairfax VA, Detroit MI,
Sponsor: Frontier Medicines Corporation

Sex: All

Age: 18+

Code: NCT06244771

Phase 1, Phase 2, Recruiting

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

for
Metastatic Uveal Melanoma, Cutaneous Melanoma,
Location: Philadelphia PA, Durham NC, Cincinnati OH, Nashville TN,
Sponsor: IDEAYA Biosciences

Sex: All

Age: 18+

Code: NCT03947385

Phase 1, Phase 2, Recruiting

GOLD: Brief Intervention to Reduce Anxiety and Promote Resilience in Families of Youth With Cancer

for
Cancer
Location: San Francisco CA
Sponsor: Stanford University

Sex: All

Age: 8 - 18

Code: NCT05415007

Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

for
Hodgkin Lymphoma in Remission, Leukemia in Remission,
Location: Scarborough ME, Boston MA, Providence RI, New Haven CT,
Sponsor: Children's Oncology Group

Sex: All

Age: 0+

Code: NCT01790152

Recruiting

Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal

for
Hematopoietic and Lymphoid System Neoplasm,
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT05530759

Recruiting

A Mindfulness-Based Stress Reduction Program for Improving Mental Health Outcomes for Underserved Cancer Patients in Minnesota

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 0+

Code: NCT07291011

Recruiting

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

for
Advanced Solid Tumors
Location: North Haven CT, Ottawa, Toronto, Orlando FL,
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Sex: All

Age: 18+

Code: NCT06384352

Phase 1, Recruiting

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

for
Advanced Esophageal Squamous Cell Carcinoma,
Location: Jacksonville FL
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT06265285

Phase 2, Recruiting

What is pancreatic cancer?

The pancreas sits deep behind the stomach and makes both digestive enzymes and hormones like insulin. About 92 percent of pancreatic cancers start in the enzyme making cells, and this page is mostly about those. The other 8 percent are neuroendocrine tumors, which grow more slowly, have their own trials, and a five year survival of 72 percent against 8 percent. The pancreas gives no early warning. Jaundice, back pain, weight loss and new diabetes usually appear only after the cancer has grown or spread, and fewer than 20 percent of people can have surgery at diagnosis.

Smoking roughly doubles the risk, and type 2 diabetes, extra weight, chronic pancreatitis and family history raise it. About 10 percent of cases come from inherited mutations, so guidelines now recommend genetic testing for everyone diagnosed. That can change treatment and flag relatives who should be watched. The hope comes from biology. More than 90 percent of pancreatic cancers carry a KRAS mutation. That target was called undruggable for decades. Now several RAS inhibitors are in trials, with the first Phase 3 studies recruiting. Pancreatic cancer shares risk factors with type 2 diabetes and inherited genes with breast and ovarian cancer.

Article preview image

Our guide to new treatments for pancreatic cancer covers what has been approved and what is being tested.

Research Paving The Way To A New Treatment For Pancreatic Cancer

Types of pancreatic cancer clinical trials

Who can participate in pancreatic cancer clinical trials?

What causes pancreatic cancer?

The stages of pancreatic cancer, and why they matter for trials

How to enroll in a pancreatic cancer clinical trial